1-4 of 4
David Grayzel, MD
Close
Sort by
Journal Articles

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

David Siegel, MD, PhD, Sundar Jagannath, MD, Amitabha Mazumder, MD, David Vesole, MD, Ivan Borrello, MD, Jens Sydor, PhD, Jim Wright, PhD, Jon Patterson, BS, Emmanuel Normant, PhD, Julian Adams, PhD, Kenneth Anderson, MD, David Grayzel, MD, Paul Richardson, MD
Journal: Blood
Blood (2006) 108 (11): 3579.
https://doi.org/10.1182/blood.V108.11.3579.3579
Published: 2006
Journal Articles

IPI-504, a Novel, Orally Active HSP90 Inhibitor, Prolongs Survival of Mice with BCR-ABL T315I CML and B-ALL.

Cong Peng, MS, Julia Brain, PhD, Yiguo Hu, MD, Linghong Kong, MD, PhD, David Grayzel, MD, Roger Pak, PhD, Margaret Read, PhD, Shaoguang Li, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2183.
https://doi.org/10.1182/blood.V108.11.2183.2183
Published: 2006
Journal Articles

Hsp-90 Inhibition Decreases Survival of BCR-ABL T315I Leukemic Stem Cells in Mice.

Cong Peng, MS, Julia Brain, PhD, Yiguo Hu, MD, Linghong Kong, MD, PhD, Ami Goodrich, David Grayzel, MD, Roger Pak, PhD, Margaret Read, PhD, Shaoguang Li, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2184.
https://doi.org/10.1182/blood.V108.11.2184.2184
Published: 2006
Journal Articles

Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Sundar Jagannath, MD, David Siegel, MD, Paul Richardson, MD, Amitabha Mazumder, MD, Jens Sydor, PhD, Jill Goddard, John Walker, Jon Patterson, Emmanuel Normant, PhD, Jeffrey Tong, PhD, Vito Palombella, PhD, Ken Anderson, MD, Julian Adams, PhD, David Grayzel, MD
Journal: Blood
Blood (2005) 106 (11): 2560.
https://doi.org/10.1182/blood.V106.11.2560.2560
Published: 2005